Celularity Inc
Allogeneic, cryopreserved cell therapies and advanced biomaterials derived from postpartum placenta
- Sector
- Biotech
- Headquarters
- FLORHAM PARK, NJ
- Founded
- 2018
- Latest Form D
- $2M, Nov 2025
- Total capital
- $41.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $41.8M
- 5 Form D · last Nov 2025
- 12 months since last filing
- Federal contracts
- $80K
- 1 award · Veterans Affairs
- Rank in Biotech#337 of 4373
- Granted patents
- 6
- 34 pending · first 2021
- Rank in peer group#131 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$2M
- Private capital raisedForm D · SEC · 4th filing$1M
- Private capital raisedForm D · SEC · 3rd filing$2M
- Private capital raisedForm D · SEC · 2nd filing$6.8M
- Private capital raisedForm D · SEC · 1st filing$30M
- Federal contractVeterans Affairs · Lease Renewal For Ultra-mist Therapy Systems Service Igf::ot::igf$80K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
50months
from Celularity Inc’s first federal award to its first private round.
- First federal award · Apr 2018
- Veterans Affairs · $80K
- First Form D · May 2022
- $30M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#131 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew PecoraDirectorNamed in SEC Form D filings
- Andrew von EschenbachDirectorNamed in SEC Form D filings
- Beth SteinbrennerExecutive OfficerNamed in SEC Form D filings
- Bill R. MarisDirectorNamed in SEC Form D filings
- Bill WallerExecutive OfficerNamed in SEC Form D filings
- Carlos RamirezExecutive OfficerNamed in SEC Form D filings
Show all 32 people
- Curtis QuigleyExecutive OfficerNamed in SEC Form D filings
- David R. DemingDirectorNamed in SEC Form D filings
- David LemusDirectorNamed in SEC Form D filings
- Diane A. ParksDirectorNamed in SEC Form D filings
- Geoffrey A. LingDirectorNamed in SEC Form D filings
- Gertjan BartlemaExecutive OfficerNamed in SEC Form D filings
- Henry R. BrockExecutive OfficerNamed in SEC Form D filings
- Henry R. JiDirectorNamed in SEC Form D filings
- Jaisim ShahDirectorNamed in SEC Form D filings
- Jodi GurneyExecutive OfficerNamed in SEC Form D filings
- John R. HainesExecutive OfficerNamed in SEC Form D filings
- John SculleyDirectorNamed in SEC Form D filings
- John R. ScullyDirectorNamed in SEC Form D filings
- Joseph R. DosSantosExecutive OfficerNamed in SEC Form D filings
- Joseph KaminskiExecutive OfficerNamed in SEC Form D filings
- Kok Thay LimDirectorNamed in SEC Form D filings
- Mohit R. BhatiaExecutive OfficerNamed in SEC Form D filings
- Nassir HabboubiExecutive OfficerNamed in SEC Form D filings
- Peter A. DiamandisDirectorNamed in SEC Form D filings
- Robert J. HaririExecutive Officer, DirectorNamed in SEC Form D filings
- Stephen A. BrigidoExecutive OfficerNamed in SEC Form D filings
- Timothy SmithExecutive OfficerNamed in SEC Form D filings
- Tim SmithExecutive OfficerNamed in SEC Form D filings
- Vincent A. LeVienDirectorNamed in SEC Form D filings
- William R. WallerExecutive OfficerNamed in SEC Form D filings
- Xiaokui ZhangExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingDermal Rejuvenation Composition Comprising Placenta Derived Biomaterial And Uses ThereofUSPTOApplication 19145935
- PendingCompositions And Methods For Treating CancerUSPTOApplication 19129085
- PendingHuman Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereofUSPTOApplication 18921811
Show all 40 patent records
- Dermal Rejuvenation Composition Comprising Placenta Derived Biomaterial And Uses ThereofJul 23, 2026 · Application 19145935Pending
- Compositions And Methods For Treating CancerJul 2, 2026 · Application 19129085Pending
- Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereofMay 28, 2026 · Application 18921811Pending
- Method For Modulating Glucagon-like Peptide 1 (GLP-1) Agonist Induced Muscle LossJan 1, 2026 · Application 19094351Pending
- Cleavage Resistant CD16 Constructs And Uses ThereofSep 25, 2025 · Application 18728298Pending
- Placenta-dervied Nk Cells As A Senol Ytic For Therapeutic And Other UsesSep 4, 2025 · Application 18293243Pending
- Multi-layer Amniotic Tissue Grafts And Uses ThereofJul 25, 2024 · Application 18555412Pending
- Populations Of Natural Killer Cells Comprising A Cleavage Resistant CD16Nov 9, 2023 · Application 17597968Pending
- Cultivation Of Placenta To Isolate ExosomesOct 5, 2023 · Application 18205303Pending
- Treatment Of Lymphedema And Related Conditions Using Placental Adherent CellsSep 28, 2023 · Application 18201907Pending
- Treatment Of Inflammatory Diseases Using Placental Stem CellsAug 15, 2023 · US 11,723,930Granted
- Use Of Placental Stem Cells In Treatment Of Acute Kidney InjuryJul 11, 2023 · US 11,696,930Granted
- Placenta-derived Adherent (pda) Stem Cell For The Treatment Of Adults With SARS-COV-2 Related Acute Respiratory Failure And Ards (COVID-19)Jul 6, 2023 · Application 17998199Pending
- Exosomes For Disease TreatmentJun 15, 2023 · Application 17596827Pending
- Natural Killer Cells And ILC3 Cells And Uses ThereofMay 11, 2023 · Application 18056088Pending
- Treatment Of Premature Birth ComplicationsMar 23, 2023 · Application 18057487Pending
- Enhanced Placental Stem Cells And Uses ThereofMar 16, 2023 · Application 18048291Pending
- Expansion Of Natural Killer Cells And ILC3 Cells With Novel Aromatic CompoundsJan 26, 2023 · Application 17309449Pending
- Enhanced Placental Stem Cells And Uses ThereofNov 29, 2022 · US 11,512,282Granted
- Genetically Modified Natural Killer CellsNov 3, 2022 · Application 17645004Pending
- Populations Of Natural Killer Cells Comprising A CD38 Chimeric Antigen ReceptorSep 1, 2022 · Application 17630079Pending
- Populations Of Natural Killer Cells For Treating CancersAug 25, 2022 · Application 17619242Pending
- Methods Of Generating Natural Killer CellsAug 18, 2022 · Application 17733321Pending
- Aromatic Compounds For Use In Activating Hematopoietic Stem And Progenitor CellsAug 11, 2022 · Application 17297841Pending
- Placenta-derived Adherent Cell Exosomes And Uses ThereofAug 4, 2022 · Application 17495985Pending
- Placenta Derived Adherent Cells For Improved XenoplantationMay 26, 2022 · Application 17439671Pending
- Placenta-derived Allogeneic Car-t Cells And Uses ThereofApr 21, 2022 · Application 17309451Pending
- Methods And Compositions For Treatment Of Bone Defects With Placental Cell PopulationsMar 31, 2022 · Application 17302855Pending
- Human Placental Collagen Compositions And Methods Of Making And Using The SameMar 31, 2022 · Application 17302831Pending
- Treatment Of Diabetic Peripheral Neuropathy Using Placental CellsMar 10, 2022 · Application 17455322Pending
- Placental Derived Natural Killer Cells For Treatment Of Coronavirus InfectionsJan 6, 2022 · Application 17163316Pending
- Methods Of Treating Acute Myeloid Leukemia And Multiple Myeloma Using Natural Killer CellsNov 23, 2021 · US 11,180,731Granted
- Placenta-derived Adherent Cell Exosomes And Uses ThereofNov 16, 2021 · US 11,173,182Granted
- Cell Composition And Methods Of Making The SameSep 23, 2021 · Application 17340979Pending
- Devices And Methods For Thawing Biological MaterialAug 19, 2021 · Application 17302353Pending
- Treatment Of Pain Using Placental Stem CellsAug 17, 2021 · US 11,090,339Granted
- Angiogenesis Using Stimulated Placental Stem CellsJul 29, 2021 · Application 17143866Pending
- Methods For Isolation Of PlateletsJul 29, 2021 · Application 17223768Pending
- Methods Of Tissue GenerationMay 20, 2021 · Application 16909567Pending
- Tumor Suppression Using Human Placenta-derived Intermediate Natural Killer Cells And Immunomodulatory CompoundsApr 29, 2021 · Application 16890716Pending
Related companies, and why
- FLUENT BIOSCIENCES INCSimilar federal contract value in Biotech · $96K in contracts
- Bellbrook Labs, LLCSimilar federal contract value in Biotech · $90K in contracts
- FINA BIOSOLUTIONS LLCSimilar federal contract value in Biotech · $83K in contracts
- AUM LIFETECH INCSimilar federal contract value in Biotech · $80K in contracts
- PRIMETIME LIFE SCIENCES, LLCSimilar federal contract value in Biotech · $79K in contracts
- Nexome Genomics Inc.Similar federal contract value in Biotech · $78K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .